98%
921
2 minutes
20
Twenty-three polymyxin analogs with variations at nine amino acid positions were synthesized and assessed for antimicrobial activity and renal cytotoxicity. Compounds , , , and (MIC = 0.125-4 μg/mL) had similar or stronger activities against susceptible and drug-resistant strains of , , , and compared to polymyxin B (MIC = 1-2 μg/mL). Most synthesized compounds (50% cytotoxic concentration, CC ≥ 200 μg/mL) exhibited lower cytotoxicity than polymyxin B (CC = 99 ± 6 μg/mL). Polymyxin S showed high plasma stability and strong efficacy in a mouse systemic infection model (ED = 0.9 mg/kg) against NDM-1-producing , suggesting that it is a potential candidate for drug development. The activity and cytotoxicity results indicated that the amino acids at positions 2, 3, 6, and 7 might be replaced. Effects on activity and cytotoxicity linked to changes in the number of positively charged amino acids varied among different cyclopeptide skeletons, but the underlying mechanisms are unknown.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsinfecdis.0c00056 | DOI Listing |
Nat Rev Cancer
September 2025
Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Neurotoxicity is a common and potentially severe adverse effect from conventional and novel cancer therapy. The mechanisms that underlie clinical symptoms of central and peripheral nervous system injury remain incompletely understood. For conventional cytotoxic chemotherapy or radiotherapy, direct toxicities to brain structures and neurovascular damage may result in myelin degradation and impaired neurogenesis, which eventually translates into delayed neurodegeneration accompanied by cognitive symptoms.
View Article and Find Full Text PDFChem Res Toxicol
September 2025
University of Texas Medical Branch, Galveston, Texas 77555, United States.
Glioblastoma (GBM) is a lethal brain tumor with limited therapeutic options. Temozolomide (TMZ), a standard-of-care chemotherapeutic agent, exerts its cytotoxicity by alkylating DNA, which triggers a DNA damage response and depletes ATP and NAD. However, TMZ also releases the byproduct 4-amino-5-imidazole carboxamide (AIC), which is believed to be a benign metabolite.
View Article and Find Full Text PDFSteroids
September 2025
Department of Chemical Sciences, University of Naples Federico II, Naples I-80126, Italy.
Antimicrobial resistance is currently one of the most serious and alarming threats to human health; therefore, the identification of novel antimicrobial agents is a compelling need. Recently, we identified the heterocyclic steroid PYED-1 as a novel promising antibacterial and antibiofilm agent. In an effort to broaden the repertoire of active compounds and elucidate the structural features responsible for their antibacterial activity, two novel derivatives of PYED-1 have been conceived herein.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
Key Laboratory of Animal Vaccine Development, Ministry of Agriculture and Rural Affairs, College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China. Electronic address:
Group A Rotavirus (RVA) poses a significant health risk. Unfortunately, there are currently no the Food and Drug Administration (FDA) approved antiviral compounds available for treating RVA-induced diarrhea. The lectin-like domain of VP8* plays an important role in the RVA lifecycle.
View Article and Find Full Text PDFCancer Lett
September 2025
Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Huaian, 223300, Jiangsu Province, China; Key Laboratory of Autoimmune Diseases of Huaian City, Huaian, 223300, Jiangsu Pr
CAR-T cell therapy, as a representative technology in cancer immunotherapy, has demonstrated notable success in the treatment of hematologic malignancies; however, a significant proportion of patients fail to achieve sustained remission. Through the analysis of bone marrow sequencing data prior to CD19 CAR-T cell therapy, we identified cellular adhesion as a pivotal factor influencing clinical outcomes. We developed a model to predict B-ALL treatment efficacy based on the core genes associated with cellular adhesion, which was validated in our clinical cohort.
View Article and Find Full Text PDF